Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC388 in Advanced/Metastatic Renal Cell Carcinoma
NCT01831973Phase 2Completed
- Sponsor
- Taiwan Liposome Company
- Start
- Nov 2012
- Primary completion
- Mar 2015
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lipotecan in renal cell carcinoma (RCC), sponsored by Taiwan Liposome Company. Started Nov 2012; status: completed.
02
Drugs
lipotecan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01831973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01831973.